MA55497A - Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires - Google Patents
Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoiresInfo
- Publication number
- MA55497A MA55497A MA055497A MA55497A MA55497A MA 55497 A MA55497 A MA 55497A MA 055497 A MA055497 A MA 055497A MA 55497 A MA55497 A MA 55497A MA 55497 A MA55497 A MA 55497A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- pharmaceutical compositions
- novel compounds
- inflammatory disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1904373.6A GB201904373D0 (en) | 2019-03-29 | 2019-03-29 | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55497A true MA55497A (fr) | 2022-02-09 |
Family
ID=66442982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055497A MA55497A (fr) | 2019-03-29 | 2020-03-24 | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220218679A1 (fr) |
| EP (1) | EP3947378A1 (fr) |
| JP (1) | JP2022526364A (fr) |
| KR (1) | KR20210145238A (fr) |
| CN (1) | CN113646305A (fr) |
| AR (1) | AR118521A1 (fr) |
| AU (1) | AU2020252038A1 (fr) |
| BR (1) | BR112021019055A2 (fr) |
| CA (1) | CA3134736A1 (fr) |
| CO (1) | CO2021014223A2 (fr) |
| GB (1) | GB201904373D0 (fr) |
| IL (1) | IL286677A (fr) |
| MA (1) | MA55497A (fr) |
| MX (1) | MX2021011576A (fr) |
| SG (1) | SG11202110644WA (fr) |
| TW (1) | TW202102501A (fr) |
| WO (1) | WO2020200900A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113243338A (zh) * | 2021-05-14 | 2021-08-13 | 福州大学 | 一种小鼠缺血性卒中模型的构建与评估方法 |
| CN117177965B (zh) * | 2021-12-23 | 2024-04-30 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
| WO2024133560A1 (fr) * | 2022-12-21 | 2024-06-27 | Dark Blue Therapeutics Ltd | Dérivés imidazo[1,2-a]pyridines et imidazo[1,2-a]pyrazines en tant qu'inhibiteurs de mllt1 et mllt3 |
| EP4389747A1 (fr) * | 2022-12-21 | 2024-06-26 | Dark Blue Therapeutics Ltd | Composés imidazo[1,2-a]pyridiniques et imidazo[1,2-a]pyraziniques en tant qu'inhibiteurs de mllt1 et mllt3 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012129258A1 (fr) * | 2011-03-22 | 2012-09-27 | Merck Sharp & Dohme Corp. | Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole |
| GB201401086D0 (en) * | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CU20180006A7 (es) * | 2015-07-15 | 2018-06-05 | Aurigene Discovery Tech Ltd | Compuestos de indazaol y azaindazol como inhibidores de irak-4 |
| GB201518456D0 (en) * | 2015-10-19 | 2015-12-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
| EP3535273A1 (fr) * | 2016-11-02 | 2019-09-11 | H. Hoffnabb-La Roche Ag | Dérivés pyrazolo [1,5a]pyrimidine en tant que modulateurs d'irak 4 |
-
2019
- 2019-03-29 GB GBGB1904373.6A patent/GB201904373D0/en not_active Ceased
-
2020
- 2020-03-24 SG SG11202110644WA patent/SG11202110644WA/en unknown
- 2020-03-24 CN CN202080025098.XA patent/CN113646305A/zh active Pending
- 2020-03-24 EP EP20715295.0A patent/EP3947378A1/fr active Pending
- 2020-03-24 AU AU2020252038A patent/AU2020252038A1/en not_active Abandoned
- 2020-03-24 MA MA055497A patent/MA55497A/fr unknown
- 2020-03-24 MX MX2021011576A patent/MX2021011576A/es unknown
- 2020-03-24 BR BR112021019055A patent/BR112021019055A2/pt unknown
- 2020-03-24 KR KR1020217035254A patent/KR20210145238A/ko active Search and Examination
- 2020-03-24 JP JP2021557761A patent/JP2022526364A/ja active Pending
- 2020-03-24 US US17/599,465 patent/US20220218679A1/en active Pending
- 2020-03-24 CA CA3134736A patent/CA3134736A1/fr active Pending
- 2020-03-24 WO PCT/EP2020/058064 patent/WO2020200900A1/fr unknown
- 2020-03-27 AR ARP200100870A patent/AR118521A1/es unknown
- 2020-03-27 TW TW109110404A patent/TW202102501A/zh unknown
-
2021
- 2021-09-26 IL IL286677A patent/IL286677A/en unknown
- 2021-10-25 CO CONC2021/0014223A patent/CO2021014223A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210145238A (ko) | 2021-12-01 |
| GB201904373D0 (en) | 2019-05-15 |
| SG11202110644WA (en) | 2021-10-28 |
| AU2020252038A1 (en) | 2021-11-25 |
| US20220218679A1 (en) | 2022-07-14 |
| CN113646305A (zh) | 2021-11-12 |
| EP3947378A1 (fr) | 2022-02-09 |
| CA3134736A1 (fr) | 2020-10-08 |
| JP2022526364A (ja) | 2022-05-24 |
| MX2021011576A (es) | 2021-10-13 |
| TW202102501A (zh) | 2021-01-16 |
| AR118521A1 (es) | 2021-10-20 |
| CO2021014223A2 (es) | 2021-11-19 |
| IL286677A (en) | 2021-10-31 |
| WO2020200900A1 (fr) | 2020-10-08 |
| BR112021019055A2 (pt) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA55497A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires | |
| MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA52118A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| LU92577B1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose | |
| MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA54544A (fr) | Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale | |
| GB201911868D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| IL286688A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation | |
| MA50069A (fr) | Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique | |
| MA52960A (fr) | Compositions et procédés pour la réduction ou le traitement de la fibrose | |
| MA54873A (fr) | Compositions et méthodes pour le traitement de troubles neurocognitifs |